@article {2606, title = {Effects of Hydrolyzed Marine Collagen Peptide Supplementation Combined with Phytonutrients on Skin Biophysical Parameters and Extracellular Matrix Biomarkers in Thai Women: A Prospective Clinical Study}, journal = {Pharmacognosy Journal}, volume = {18}, year = {2026}, month = {June 2026}, pages = {157-163}, type = {Original Article}, chapter = {157}, abstract = {

Background: Skin aging involves progressive deterioration of extracellular matrix components. This study investigated the effects of hydrolyzed marine collagen peptide supplementation combined with phytonutrients on skin biophysical parameters and dermal biomarkers in Thai women. Methods: Sixtythree Thai women aged 40{\textendash}60 years received daily supplementation (10,000 mg marine collagen peptides, Chlorella, grape seed extract, rice ceramides) for 12 weeks. Assessments included Antera 3D imaging, Cutometer elasticity measurements, Tewameter barrier function evaluation, and Corneometer hydration analysis. A subset (n=20) underwent suction blister biopsy for dermal biomarker analysis. Results: Significant improvements were observed in Cutometer parameters: R5 net elasticity (p\<0.001), R6 viscoelasticity (p=0.018), and R7 biological elasticity (p=0.003). Transepidermal water loss (TEWL) decreased by 12.1\% (p=0.007). Antera 3D analysis revealed a significant increase in wrinkle width (p=0.021), indicating wrinkle flattening. Biomarker analysis showed significant increases in fibrillin-1 (+8.34\%, p=0.005) and biglycan (+22.91\%, p=0.036). Glogau photoaging classification improved in 23.8\% of participants. Conclusions: Marine collagen peptide supplementation combined with phytonutrients significantly improved skin elasticity and barrier function, with molecular evidence of extracellular matrix enhancement in Thai women.

}, keywords = {Antera 3D, Barrier function, Cutometer, Fibrillin-1, Marine collagen peptides, Skin elasticity}, doi = {10.5530/pj.2026.18.129}, author = {Uratchat Vichaidit and Pratya Phetkate and Parunkul Tungsukruthai and Kammal Kumar Pawa and Panlop Chakkavittumrong and Chuntida Kamalashiran} } @article {2295, title = {Efficacy and Safety of Traditional Transdermal Patch (Ya-Pok- Dud-Pid) in Primary Knee Osteoarthritis Patients: A Randomized Controlled Trial}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {June 2024}, pages = {570-575}, type = {Original Article}, chapter = {570}, abstract = {

Background: Patients with Knee Osteoarthritis (KOA) have a progressive decline in their social and physical abilities, which affects their quality of life. The Thai Traditional Transdermal Patch (Ya-Pok-Dud- Pid; YP) has been widely used for the treatment of KOA. Objective: To determine the clinical efficacy and safety of YP in comparison with diclofenac gel (DG) for the treatment of KOA. Methods: 74 primary KOA Patients were enrolled and randomly assigned to YP groups or DG groups. The outcomes were assessed the Visual Analog Scale (VAS), Time Up and Go (TUG), Active Knee Flexion (AKF) and Passive Knee Flexion, chair sit and reach, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results: YP and DG significantly improved VAS, TUG, AKF, PKF, chair sit and reach, and WOMAC (p \< 0.05). Remarkably, YP experienced the same immediate pain relief after day 1 treatment as DG. The VAS scores of the YP group exhibited a significant reduction from 60{\textpm}11.06 to 38.92{\textpm}17.76, while DG decreased VAS score from 61.24{\textpm}17.84 to 39.19{\textpm}20.05 (p \<0.001). However, there was no significant difference between the two treatment groups. For adverse event, skin reaction (rash, itchy, and dry skin) was noted in the YP group because of the participant receiving YP for an extended period. Altogether, YP has a similar effect to diclofenac gel on pain severity and physical function in patients with knee osteoarthritis. Conclusion: YP is recommended as a natural therapeutic agent with efficacy and safety treatment for knee osteoarthritis.

}, keywords = {Diclofenac, Osteoarthritis of knee, Traditional, Transdermal Patch}, doi = {10.5530/pj.2024.16.89}, author = {Chutharat Saereewat and Kusuma Sriyakul and Parunkul Tungsukruthai and Sunyarn Niempoog and Sucharat Tungsukruthai and Chuntida Kamalashiran} } @article {2291, title = {Renal Resistive Index and Estimated Glomerular Filtration Rate in Nondiabetic Chronic Kidney Disease Stage 3: A Cross-Sectional Analytical Study}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {June 2024}, pages = {538-544}, type = {Original Article}, chapter = {538}, abstract = {

Background: Renal resistive index (RRI) and estimated glomerular filtration rate (eGFR) are predictive markers for chronic kidney disease (CKD) progression. Aim: To evaluate RRI value, eGFRcr-cys and renal biomarker in nondiabetic patients with CKD stage 3 in Bangkok, Thailand. Methods: A cross-sectional analytical analysis was conducted involving nondiabetic patients with CKD stage 3, aged 35-85 years. Ultrasound was used to assess the RRI of arteries in both kidneys. Patients underwent assessments of serum and urine 24-hour. Results: Among the 61 participants (67.2\% male; mean age 69.03 {\textpm} 12.59 years), the mean eGFRcr-cys was 41.63 {\textpm} 8.64 mL/min/1.73 m{\texttwosuperior}, and the mean RRI was 0.65 {\textpm} 0.06. Patients were categorized into three RRI groups: low (\<0.65, n=35), intermediate (0.65-0.70, n=14), and high (\>0.70, n=12). The high RRI group showed a mean RRI of 0.73 {\textpm} 0.05 (p \< 0.01). Among those with high RRI group were significant decreased right kidney size (p\<0.05) and they had a lower BMI, averaging 22.49 {\textpm} 3.48. An increase in PP (59.66 {\textpm} 13.84, p=0.04) was also significant in this group. The correlations coefficient of RRI value showed a significant positive correlation with age (p\<0.05) and significant negative with BMI (p\<0.05). In addition, eGFRcr-cys displayed a significant negative correlation with UAGT and 24hUP (p\<0.05) and a significant while eGFRcr-cys positive correlation with both kidney size and urine iNOS(p\<0.01). Conclusion: An increase in RRI is inversely linked to age, BMI, and PP. Lower eGFR is correlated with factors that cause CKD progression.

}, doi = {10.5530/pj.2024.16.85}, author = {Patnaree Wongmanit and Kusuma Sriyakul and Parunkul Tungsukruthai and Ouppatham Supasyndh and Pratya Phetkate} } @article {2235, title = {Safety Assessment of Oral Lysiphyllum strychnifolium Aqueous Extract in Healthy Volunteers}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {February 2024}, pages = {235-240}, type = {Research Article}, chapter = {235}, abstract = {

Background: Lysiphyllum strychnifolium (LS), widely known as Ya nang daeng in Thailand, is a traditional herbal remedy that has long been used to promote health and treat diverse health conditions, especially detoxification, by alleviating the severity of symptoms and lowering the risks associated with toxic exposures. Although it is extensively used in Thailand, human safety studies have been lacking. Thus, this study aimed to examine the safety of using LS capsules in healthy participants through a Phase I clinical trial. Objective: This study aimed to investigate the safety of aqueous extract of LS in twenty-four healthy Thai participants. Method: The participants were received 1,000 mg of LS aqueous extract each morning before their meals for seven days. All participants were examined safety assessment including history taking, physical examination, and laboratory tests at day 0, 8 and 14 (follow-up). Results: The findings showed that there were no significant side effects or abnormalities found during the history taking, physical examination, or laboratory evaluation. Particularly, when compared to baseline, participants who received LS experienced statistically significant reductions in blood sugar, triglyceride, LDL cholesterol, and creatinine (P \< 0.05), but still within normal ranges. Conclusions: Dietary supplementation with 1,000 mg of LS aqueous extract per day may have a beneficial effect on blood sugar and cholesterol management while remaining safe for healthy people.

}, keywords = {Clinical study, Healthy volunteers, Lysiphyllum strychnifolium, Safety, Yanang Daeng}, doi = {10.5530/pj.2024.16.34}, author = {Piracha Jumpa-ngern and Parunkul Tungsukruthai and Chuntida Kamalashiran and Somboon Kietinun and Kesara Na- Bangchang and Kusuma Sriyakul} } @article {2135, title = {The Investigation of The Network Pharmacology and Mechanism of Action of Centella Asiatica Extract on The Atopic Dermatitis Model}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {October 2023}, pages = {881-890}, type = {Research Article}, chapter = {881}, abstract = {

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin condition which has a negative impact on children health. The well-known medicinal plant Centella asiatica extract (CE) is used in herbal skin care products to produce various pharmacological effects in dermatology. However, the molecular target of CE in suppressing inflammatory is largely unknown. Objective: the aim of this study was to examine anti-inflammatory properties and network pharmacology of CE in lipopolysaccharide (LPS)- induced AD in vitro model. Method: RAW264.7 cells were pre-treated with CE and then were stimulated with LPS and then were investigated cell viability, NO production, and the levels of pro-inflammatory mediators. In addition, the Search Tool for Retrieval of Interacting Genes (STRING), SwissTargetPrediction and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to construct the defined mechanism of action and network pharmacology. Results: CE showed the potent inhibitory effects on LPS-induced NO. In addition, CE significantly suppressed the expression of iNOS and COX-2, as well as the production of IL-2, IL-6, IL-10, and TNF- α. Furthermore, the network pharmacological analysis revealed the potential role of CE in biological processes such as regulating JAK/STATs pathway and inhibiting proinflammatory cytokines both of which were linked to AD pathogenesis. Conclusion: Our findings confirm our hypothesis that CE could be developed as a therapeutic therapy for atopic dermatitis due to its pharmacological action and signaling mechanism in the modulation of allergic skin inflammation.

}, keywords = {Atopic dermatitis, Centella asiatica, Network pharmacology, Skin inflammation.}, doi = {10.5530/pj.2023.15.168}, author = {Sucharat Tungsukruthai and Runtikan Pochairach and Aungkana Krajarng and Piracha Jumpa-ngern and Parunkul Tungsukruthai} } @article {2149, title = {Safety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {December 2023}, pages = {976-986}, type = {Original Article}, chapter = {976}, abstract = {

Background: Chronic kidney disease is a major public health issue, and due to resource constraints, many can{\textquoteright}t access dialysis. C. citratus, lemongrass is globally prevalent and known to increase urine output without toxicity. Objective: To examine the safety of C. citratus in patients with CKD stage 3. Materials and Methods: The major compound of C. citratus was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or C. citratus groups. The control group received a placebo, whereas the C. citratus group received 900 mg of C. citratus daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. Results: HPLC showed C. citratus contains of phenolic compounds. Clinically, C. citratus group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p \< 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p \< 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na+, K+, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. Conclusion: Dietary supplementation with C. citratus may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.

}, keywords = {Chronic Kidney Disease, CKD stage 3, Cymbopogon citratus Stapf., Lemongrass, Safety}, doi = {10.5530/pj.2023.15.181}, author = {Patnaree Wongmanit and Parunkul Tungsukruthai and Pratya Phetkate and Daraporn Rungprai and Sucharat Tungsukruthai and Ouppatham Supasyndh and Kusuma Sriyakul} }